Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 13/20 | 0.63 |
| ▸ | MME | P08473 | 11/20 | 0.63 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.55 |
| ▸ | MMP8 | P22894 | 1/20 | 0.54 |
| ▸ | MMP14 | P50281 | 1/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 1/20 | 0.53 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | PLAU | P00749 | 1/20 | 0.52 |
| ▸ | PLAT | P00750 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7716999 | 0.84 | ECE1 (0.60) | ECE1MMEACE2CTSLCTSS | |
| SCHEMBL10958149 | 0.83 | ECE1 (0.59) | ECE1MMEACE2CTSLCTSS | |
| Bromide SCHEMBL1436853 | 0.83 | ECE1 (0.59) | ECE1MMEACE2CTSLCTSS | |
| SCHEMBL7291199 | 0.83 | ECE1 (0.61) | ECE1MMEACE2F2PLAU | |
| SCHEMBL21300810 | 0.82 | ECE1 (0.61) | ECE1MMEACE2MMP8MMP14 | |
| SCHEMBL28101997 | 0.82 | ECE1 (0.58) | ECE1MMEACE2MMP8MMP14 | |
| SCHEMBL16856590 | 0.82 | ECE1 (0.58) | ECE1MMEACE2MMP8MMP14 | |
| SCHEMBL14334539 | 0.80 | ECE1 (0.63) | ECE1MMEACE2F2PLAU | |
| SCHEMBL7328702 | 0.80 | ECE1 (0.63) | ECE1MMEACE2F2PLAU | |
| SCHEMBL28370653 | 0.79 | CTSL (0.62) | ECE1MMECTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088730-A1 | USE OF ANGIOTENSIN CONVERTING ENZYME (ACE) DOMAIN SPECIFIC INHIBITORS TO INHIBIT OR ENHANCE CYTOKINE PRODUCTION AND ALTER IMMUNE RESPONSE | CEDARS-SINAI MEDICAL CENTER (US) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088730-A1 | USE OF ANGIOTENSIN CONVERTING ENZYME (ACE) DOMAIN SPECIFIC INHIBITORS TO INHIBIT OR ENHANCE CYTOKINE PRODUCTION AND ALTER IMMUNE RESPONSE | ACE, ACE2, AGT | ECE1 10/4885MME 9/4885ACE2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.